8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)
Published . Updated .
Key takeaways
- 8-K - INOVIO PHARMACEUTICALS filed an 8-K with the SEC on Nov 2 (a notice of a material company event).
- Exposed: INO
- Market reaction: INO +141.7% after three sessions
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - INOVIO PHARMACEUTICALS filed an 8-K with the SEC on Nov 2 (a notice of a material company event).
Directly affected
- INO Inovio Pharmaceuticals+30.8% 13d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- LLY Eli Lilly and+25.1% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- JNJ Johnson & Johnson+12.1% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- PFE Pfizer+5.2% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- MRK Merck+3.5% 30d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| INO | +45.40% | +54.28% | base | +216.67% | +175.00% | +169.17% | +141.67% |
| XLV | -3.03% | -2.77% | base | -0.14% | -0.48% | +2.59% | +0.17% |
| XBI | -3.49% | +0.99% | base | -2.51% | -0.66% | +2.01% | -4.85% |
| LLY | -9.71% | -8.92% | base | -0.37% | -0.54% | +0.07% | -3.00% |
| JNJ | -2.53% | -0.72% | base | -0.98% | -2.59% | +1.13% | -0.32% |
| PFE | -2.33% | -3.34% | base | +0.69% | -1.70% | +0.95% | -2.03% |
| MRK | -5.94% | -5.65% | base | -0.74% | -3.26% | +0.55% | -1.48% |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-11-02 AccNo: 0001193125-26-442648 Size: 2 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
Inovio Pharmaceuticals (INO) since “8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer),” compared with the market
Since the first closing price after “8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer),” Inovio Pharmaceuticals (INO) is -11.21%.
| Company | When | Move | Status |
|---|---|---|---|
| Inovio Pharmaceuticals (INO) | that day | +216.67% | final price |
| Inovio Pharmaceuticals (INO) | the next day | +175.00% | final price |
| Inovio Pharmaceuticals (INO) | two days later | +169.17% | final price |
| Inovio Pharmaceuticals (INO) | three days later | +141.67% | final price |
| Inovio Pharmaceuticals (INO) | three days earlier | +54.28% | final price |
| Inovio Pharmaceuticals (INO) | five days earlier | +45.40% | final price |
| JNJ | that day | -0.98% | final price |
| JNJ | the next day | -2.59% | final price |
| JNJ | two days later | +1.13% | final price |
| JNJ | three days later | -0.32% | final price |
| JNJ | three days earlier | -0.72% | final price |
| JNJ | five days earlier | -2.53% | final price |
| LLY | that day | -0.37% | final price |
| LLY | the next day | -0.54% | final price |
| LLY | two days later | +0.07% | final price |
| LLY | three days later | -3.00% | final price |
| LLY | three days earlier | -8.92% | final price |
| LLY | five days earlier | -9.71% | final price |
| MRK | that day | -0.74% | final price |
| MRK | the next day | -3.26% | final price |
| MRK | two days later | +0.55% | final price |
| MRK | three days later | -1.48% | final price |
| MRK | three days earlier | -5.65% | final price |
| MRK | five days earlier | -5.94% | final price |
| PFE | that day | +0.69% | final price |
| PFE | the next day | -1.70% | final price |
| PFE | two days later | +0.95% | final price |
| PFE | three days later | -2.03% | final price |
| PFE | three days earlier | -3.34% | final price |
| PFE | five days earlier | -2.33% | final price |
| XBI | that day | -2.51% | final price |
| XBI | the next day | -0.66% | final price |
| XBI | two days later | +2.01% | final price |
| XBI | three days later | -4.85% | final price |
| XBI | three days earlier | +0.99% | final price |
| XBI | five days earlier | -3.49% | final price |
| XLV | that day | -0.14% | final price |
| XLV | the next day | -0.48% | final price |
| XLV | two days later | +2.59% | final price |
| XLV | three days later | +0.17% | final price |
| XLV | three days earlier | -2.77% | final price |
| XLV | five days earlier | -3.03% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Gilbert Cisneros bought Eli Lilly (LLY), worth $1,001 - $15,000 on 20 Oct 2026. That is 13 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 59 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Johnson & Johnson (JNJ) (held by a spouse), worth $15,001 - $50,000 on 7 Oct 2026. That is 26 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 33 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 38 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 59 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 73 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 39 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 75 days before publication. Filed 9 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Inovio Pharmaceuticals (INO)
Companies mentioned with this story
- INO Inovio Pharmaceuticals
Inovio Pharmaceuticals (INO) is linked, with no stored direction, high confidence in the 2 Nov 2026 story “8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer).” Reason on file: SEC 8-K filing -> direct issuer disclosure -> INO
How “8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)” reaches Inovio Pharmaceuticals (INO)
The 2 Nov 2026 story “8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)” names Inovio Pharmaceuticals (INO) because of this story.
What ties Inovio Pharmaceuticals (INO) to the headline is this: SEC 8-K filing -> direct issuer disclosure -> INO
Dates and price levels for Inovio Pharmaceuticals (INO)
INO traded between 1.07 and 2.17 across 13 sessions. The latest close on file is 1.47.
A simple score for Inovio Pharmaceuticals (INO)
14 out of 100
“8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.